Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
1 Liver Unit, Hospital Clinic, Institut d''Investigacions Biomèdiques August Pi i Sunyer and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain;2 Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas;3 J.W. Goethe University Hospital, Frankfurt, Germany;4 Auckland Hospital Clinical Studies Unit, Auckland, New Zealand;5 INSERM U954, Université de Lorraine, Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France;6 Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum, University of Bologna, Bologna, Italy;7 Medical University of Warsaw, Wolska, Warsaw, Poland;8 Imperial College Healthcare National Health Service Trust, London, United Kingdom;9 Janssen Infectious Diseases BVBA, Beerse, Belgium;10 Janssen Research and Development, Beerse, Belgium;11 Janssen Global Services, LLC, High Wycombe, United Kingdom;12 Janssen Global Services, LLC, Titusville, New Jersey
